Cartesian Therapeutics (RNAC) EBT Margin (2015 - 2026)
Cartesian Therapeutics' (RNAC) quarterly EBT Margin came in at 34156.41% in Q1 2026, down 3232086.0% year-on-year from N/an in Q1 2025, and down 329.88% on a QoQ basis from 7945.51% in Q4 2025.
Cartesian Therapeutics (RNAC) EBT Margin (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of EBT Margin data on file, last reported at 34156.41% in Q1 2026.
- On a quarterly basis, EBT Margin fell 3232086.0% year-over-year to 34156.41% in Q1 2026; TTM through Mar 2026 was 15958.83%, a 1567907.0% decrease from a year earlier, with the FY2025 full-year figure at 4987.31%, down 478577.0% from the prior year.
- EBT Margin for Q1 2026 stood at 34156.41%, down from 7945.51% in the prior quarter.
- Over the last five years, EBT Margin for RNAC reached as high as 3024.88% in Q4 2024 and fell as low as 34156.41% in Q1 2026.
- Historically, EBT Margin has averaged 3179.86% across 5 years, with a median of 230.19% in 2023.
- Across the five-year window, EBT Margin surged 540400 bps in 2024 and sank 3232086 bps in 2026, its largest moves.
- Year by year, EBT Margin stood at 33.37% in 2022, then plunged by 7229 bps to 2379.12% in 2023, then jumped by 227 bps to 3024.88% in 2024, then sank by 363 bps to 7945.51% in 2025, then sank by 330 bps to 34156.41% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 34156.41% in Q1 2026, 7945.51% in Q4 2025, and 1835.55% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cartesian Therapeutics | 226.07 Mn | 226.07 Mn | - | -34,156.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34,156.41% |
| Dec 31, 2025 | -7,945.51% |
| Mar 31, 2025 | -1,835.55% |
| Dec 31, 2024 | 3,024.88% |
| Jun 30, 2024 | -54.49% |
| Mar 31, 2024 | -425.94% |
| Dec 31, 2023 | -2,379.12% |
| Sep 30, 2023 | -137.41% |
| Jun 30, 2023 | -342.85% |
| Mar 31, 2023 | -322.97% |
| Dec 31, 2022 | 33.37% |
| Sep 30, 2022 | -39.66% |
| Jun 30, 2022 | 34.00% |
| Mar 31, 2022 | 29.65% |
| Dec 31, 2021 | 41.34% |
| Sep 30, 2021 | -8.46% |
| Jun 30, 2021 | -1.31% |
| Mar 31, 2021 | -71.22% |
| Dec 31, 2020 | -129.24% |
| Sep 30, 2020 | -209.41% |